key: cord-1052168-xhf8yg6o
authors: Zhao, Mengmeng; Wang, Menglong; Zhang, Jishou; Ye, Jing; Xu, Yao; Wang, Zhen; Ye, Di; Liu, Jianfang; Wan, Jun
title: Advances in the Relationship Between Coronavirus Infection and Cardiovascular Diseases
date: 2020-05-13
journal: Biomed Pharmacother
DOI: 10.1016/j.biopha.2020.110230
sha: 85a2db1bb25d3c369b7422b2b5f5a007175bec15
doc_id: 1052168
cord_uid: xhf8yg6o

The outbreak of coronavirus disease 2019 (COVID-19) has once again aroused people's concern about coronavirus. Seven human coronaviruses (HCoVs) have been discovered so far, including HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU115, severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus 2. Existing studies show that the cardiovascular disease increased the incidence and severity of coronavirus infection. At the same time, myocardial injury caused by coronavirus infection is one of the main factors contributing to poor prognosis. In this review, the recent clinical findings about the relationship between coronaviruses and cardiovascular diseases and the underlying pathophysiological mechanisms are discussed. This review aimed to provide assistance for the prevention and treatment of COVID-19.

HCoV-229E and HCoV-OC43 [35] were discovered in the 1960s, and HCoV-NL63 [22] and HCoV-HKU1 [26] were later discovered in upper respiratory tract infections, asthma, bronchiolitis, and pneumonia. There is evidence showing that infant, elderly and immunocompromised patients are more likely to be infected with high mortality rates [37, [62] [63] [64] . These infected patients are more likely develop severe disease states [65] [66] [67] [68] .

Varghese et al. [37] retrospectively analyzed the clinical data of 261 children with HCoV infection (including 229E, HKU1, NL63, OC43) and

found that approximately 16.5% of the children had cardiovascular disease. HCoV-infected children with cardiovascular disease are more likely to receive respiratory support and enter a pediatric intensive care unit (PICU), suggesting that the underlying cardiovascular disease increased the severity of HCoV infection in the children. Cabeça et al. found that children with heart disease are more likely to be infected by HCoVs [69] . The presence of congenital heart disease was a significant risk factor for severe coronavirus infection in children who were less than five years old [70] ( Table 1) .

Hypotension was found in a small number of patients with these four HCoV infections [70] (Table 2 ). There is no relevant evidence showing that HCoV infection can cause heart injury. However, Kim et al. reported that HCoVs were detected in children with Kawasaki disease, which is characterized by acute systemic vasculitis in childhood and may induce severe cardiovascular complications [71] . Serological tests suggest that HCoV-229E may be involved in the occurrence of Kawasaki disease [72] . Therefore, we still need to pay attention to cardiovascular complications when facing these four kinds of HCoV infection.

The severe acute respiratory syndrome [27] that broke out globally in 2003 is different from the human coronavirus described previously. It is a severe acute respiratory infection with clinical manifestations of fever and dry cough, with the lungs as the main locations of lesions. Some patients quickly develop acute respiratory distress syndrome (ARDS) and multiple organ failure with high mortality [73] [74] [75] [76] [77] .

There is much relevant evidence showing that pre-existing comorbid conditions are one of the major determinants of fatality [76, [78] [79] [80] [81] [82] [83] . It has been reported that the presence of cardiovascular diseases, such as hypertension and heart disease, is associated with adverse outcomes and mortality in SARS patients [84] [85] [86] [87] . Wong et al. reviewed the medical records of fatal cases and found that 60% of the patients who died had comorbid conditions such as hypertension and coronary artery disease [88] . Chen et al. found that patients with combined hypertension and cerebrovascular diseases are more likely to develop ARDS [89] . Another study by Hu et al. showed that the incidence rates of critical conditions and multiple organ dysfunction syndrome ( MODS ) among SARS patients with cardiovascular and cerebrovascular diseases were 1.8-fold and 1.9-fold higher than those of patients without underlying disease, suggesting that cardiovascular and cerebrovascular diseases are major risk factors for SARS patients to devolve into critical conditions and MODS and eventually lead to death [90] (Table 1) .

Regarding the cardiovascular complications of SARS patients, it was found that SARS patients had subclinical diastolic impairment without contraction involvement, and this damage may be reversible upon clinical recovery [91] . Another study by Yu et al. found that cardiovascular complications, including hypotension and tachycardia, are common in SARS patients but are usually self-limiting. Bradycardia and cardiac hypertrophy were less common, and arrhythmias were rare [92] . Acute myocardial infarction can also be seen in a few SARS patients [93] . SARS-CoV was reported to be found in 40% (7/18 patients) of heart samples from patients who died of SARS during the Toronto outbreak [76] , which might explain the myocardial damage discovered in SARS patients [89] . There are reports indicating that SARS-CoV also attacks small blood J o u r n a l P r e -p r o o f cardiovascular disease increased the mortality of MERS [108] . Banik suggested that sufficient attention should be paid to MERS patients with combined underlying diseases to reduce the occurrence of serious complications and mortality [109] (Table 1) .

Heart damage was also reported in MERS patients [110] . MERS-CoV was found in the kidneys of deceased patients but was not detected in the heart tissue, and the heart showed no significant histological changes [111, 112] . However, an animal model study clearly stated that MERS-CoV RNA could be seen in cardiac tissue, implying direct cardiac pathology [113] . The mechanism of heart injury in MERS infection remains unclear and requires more research.

COVID-19, which broke out at the end of 2019, is a disease caused by infection with SARS-CoV-2 [1, 2, 4] . Similar to SARS-CoV and MERS-CoV, SARS-CoV-2 is a β-CoV [2] . COVID-19 is similar to SARS and MERS and manifests as extensively pathological viral lung inflammation [1] .

Although similar to SARS-CoV and MERS-CoV, SARS-CoV-2 has its own characteristics [1, 114] . Early cases suggest that COVID-19 may not be as severe as SARS and MERS. However, the rapidly increasing number of cases and increasing evidence of human-to-human transmission suggest that SARS-CoV-2 is more contagious than SARS-CoV and MERS-CoV and has a lower fatality [3, 9, [115] [116] [117] . Up to April 27, 2020, the overall mortality of COVID-19 was 6.9% globally [5] . But the fatality rate is different in different regions and times, ranging from 0.7% to 13.5% [5, 118] .

The symptoms of COVID-19 infection appear after an incubation period of approximately 6.4 days [119] . Fever, fatigue, and dry cough are the main manifestations of COVID-19, and a few patients have symptoms such as nasal congestion, runny nose, sore throat, and diarrhea [2, 9, 120, 121] . Patients with severe cases often experience dyspnea and/or hypoxemia one week after onset [122] . Severe cases of COVID-19 progress rapidly to acute respiratory distress syndrome, septic shock, and metabolic acidosis, which is difficult to correct, and coagulopathy [10] .

Current case reports show that SARS-CoV-2 infection may have cardiovascular symptoms in addition to the typical respiratory symptoms. A small number of patients have atypical clinical manifestations and may start with cardiovascular symptoms such as chest tightness, palpitations and chest pain. A study by Liu et al. found that 7.3% (10/137) of patients had palpitations as the first symptom [123] . It was also reported that 2% of patients experienced chest pain during hospitalization [11] . In addition, Wang et al. found that 16.7% of patients with COVID-19 had arrhythmias [10] .

According to relevant studies [9] [10] [11] 124] , the proportion of COVID-19 patients with comorbid CVDs, such as hypertension, coronary artery disease and cerebrovascular disease, was larger than that of patients with other comorbidities or without comorbidities, suggesting that patients with CVD may be more susceptible to SARS-CoV-2 infection. Moreover, the incidence of CVD in patients with severe or fatal cases with COVID-19 was higher than that in patients with nonsevere cases or in those who survived [12, 13, 124] . According to the reports of the Chinese Center for Disease Control and Prevention, 15.7% of the deaths were hypertension, and 9% had other cardiovascular diseases, further suggesting that underlying cardiovascular diseases may be one of the important risk factors for poor prognosis in patients with COVID-19 [8] . It can be seen not only that the number of COVID-19 patients with cardiovascular disease is large but also that these patients have poor tolerance to severe pneumonia and are more likely to develop severe cases (Table 1) .

Cardiac complications such as electrocardiography abnormities, diastolic dysfunction, and acute myocardial injury were reported in patients with COVID-19 [124] [125] [126] [127] . Cases of severe myocarditis with reduced systolic function have been reported after COVID-19 [128] [129] [130] . And SARS-CoV-2 infection-related myocarditis is likely associated with myocardial injury [60, 128] . According to the study by Li et al., the most common organ damage outside the lungs was heart injury[13]. Serum myocardial necrosis markers such as hypersensitive troponin I (Hs-TnI) and creatine kinase (CK) increased to varying degrees in patients with mild and severe cases of COVID-19 [9] [10] [11] [12] [13] [14] [131] [132] [133] [134] . However, the risk of heart injury was higher in patients with severe cases, approximately 22.2% to 31% [9, 12, 126, 133, 134] , than in patients with mild cases, approximately 2% to 4% [9, 10] . The percentage of heart injury in COVID-19 patients who died, approximately 28% to 89% [12, 13, 132] , was higher than that in those who survived. N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were also reported to be increased[13, 134, 135] . Increased Hs-TnI and proBNP expression levels may be risk factors for severe illness and high mortality of COVID-19 [133] [134] [135] . Furthermore, it was found that high Hs-TnI levels were associated with increased levels of inflammation (neutrophils, IL-6, CRP, and PCT) and decreased levels of immunity (lymphocytes, monocytes, and CD4+ and CD8+ T cells), suggesting that cardiac injury may have something to do with the cytokine storm resulting from an overaggressive host immune response [131, 132] (Table 2) .

Two recent studies published in JAMA Cardiology reported the cardiovascular complications of COVID-19 in detail [60, 136] . Shi et al. found that cardiac injury was a common condition among hospitalized patients with COVID-19 in Wuhan, China, and it is associated with higher risk of inhospital mortality [136] . Guo et al. reported that Myocardial injury was significantly associated with fatal outcome of COVID-19. Myocardial injury was associated with cardiac dysfunction and arrhythmias. Inflammation may be a potential mechanism for myocardial injury [60] (Table 2 ).

J o u r n a l P r e -p r o o f COVID-19 may induce new cardiovascular diseases and / or aggravate potential cardiovascular diseases. The short-term and long-term cardiovascular effects of COVID-19 and the effects of specific treatments are unclear and need further investigation.

As the epidemic spread, SARS-CoV-2 evolved multiple subtypes. In a recent study, researchers proposed the subdivision of the global SARS-CoV-2 population into sixteen well-defined subtypes by focusing on the widely shared polymorphisms in nonstructural (nsp3, nsp4, nsp6, nsp12, nsp13 and nsp14) cistrons, structural (spike and nucleocapsid) and accessory (ORF8) genes [137] . Six virus subtypes were predominant in the population, accounting for more than 97% of the samples isolated from around the world. And the subtypes showed some geographical structure with two clusters: a smaller one comprised of isolates mostly sampled from Western hemisphere (Subtypes II, VI, IX, X and XI) and a larger one whose isolates were sampled from Western and Eastern hemispheres (Subtypes I, III, IV, V, VII, VIII, XII, XIII, XIV, XV and XVI) [137] . The researchers believed that the genetic structure determined for the SARS-CoV-2 population provides substantial guidelines for maximizing the effectiveness of trials for testing the candidate vaccines or drugs [137] .

In another earlier study, population genetic analyses of 103 SARS-CoV-2 genomes indicated that these viruses evolved into two major types (designated L and S), that are well defined by two different single nucleotide polymorphisms (SNPs) [138] . The L type (~70%) is more prevalent than the S type (~30%), but the S type was found to be the ancestral version. The L type is more aggressive and spread more quickly. And it was more prevalent in the early stages of the outbreak in Wuhan. But the frequency of the L type decreased after early January 2020 for more severe J o u r n a l P r e -p r o o f selective pressure placed by human intervention on the L type [138] . Contrary to the L type, the S-type, which is evolutionarily older and less aggressive, might have increased in relative frequency due to the weaker selective pressure [138] .

It was also reported that among the 27 viruses isolated from Wuhan, 26 (96.3%) were L type, and only 1 (3.7%) was S type [138] . However, among the other 73 viruses isolated outside Wuhan, 45 (61.6%) were L type, and 28 (38.4%) were S type [138] . This comparison suggests that the L type was significantly more prevalent in Wuhan than in other places. And recent studies about the clinical characteristics and outcomes of patients with COVID-19 in Wuhan [9] [10] [11] 139] or outside Wuhan [134, 140, 141] have showed that the mortality of COVID-19 patients and the proportion of patients with cardiac injury outside Wuhan was lower than that in Wuhan (Table 3) . Although there were many reasons for the different incidence of cardiac injury and outcome of COVID-19 in and outside Wuhan, such as the shortage of medical resources in Wuhan, the role of different SARS-CoV-2 subtypes cannot be ignored. The relationship between SARS-CoV-2 subtypes and the mortality of COVID-19 or the CVD complications need for further immediate, comprehensive studies that combine genomic data, epidemiological data, and records of the clinical symptoms of patients with coronavirus disease 2019.

According to the references above, we can see that patients with underlying CVD may be more likely to become infected with coronavirus, and CVD may be one of the risk factors for poor prognosis and high mortality of CoV infection. Few studies, however, have explored the mechanisms underlying these associations. We believe that the possible mechanisms may be related to inflammation.

Cardiovascular diseases such as hypertension, coronary heart disease, and cerebrovascular disease are all metabolic-related diseases. It has been reported that metabolic syndrome can downregulate the key mediator of the host's innate immune response to pathogenesis, affecting the function of the innate and humoral immune systems [142] . Chronic low-grade inflammatory disease has been widely recognized as a feature of coronary heart disease, and its occurrence is closely related to inflammation [143] . The occurrence of hypertension is associated with oxidative stress, inflammation and the activation of the immune system [144] . IL-6, IL-1 and tumor necrosis factor α (TNF-α) levels are higher in patients with hypertension than in patients with normal blood pressure [145] . This may explain why patients with underlying cardiovascular disease found in the clinic are more susceptible to infection.

Kulcsar et al. showed that MERS-CoV infection can lead to prolonged respiratory tract inflammation, immune cell dysfunction, and changes in the expression profile of inflammatory mediators [146] . Lymphopenia and increased inflammatory mediators were found in SARS-CoV-2 infection [147] . Immune disorders caused by SARS-CoV infection have also been reported [148] . These may lead to the exacerbation of the original cardiovascular disease, which is related to the death of some patients found in the clinic due to heart failure [88, 103, 132] . According to information released by the Shanghai Municipal Health and Family Planning Commission, the first COVID-19 death in Shanghai was in an individual who was 88 years old with a severe history of hypertension and cardiac insufficiency. An analysis of the cause of death suggested that the patient died of heart failure and systemic multiple organ dysfunction. Therefore, SARS-CoV-2 infection was just an inducement for exacerbations [124] .

Overall, the heart and lungs are inseparable in the normal physiological functions of the human body. On the one hand, comorbidities and complications of the heart increase the risk of pneumonia infection and exacerbation; on the other hand, pneumonia infection may aggravate existing cardiovascular diseases, such as increased blood pressure, increased heart failure, and the recurrence of myocardial infarction.

Fever is a common symptom in patients with coronavirus infection [9, 27, 149] . Fever promotes the immune functions of humans and some animals and decreases the pathogenicity of some microbes. Antibody production, T-cell activation, neutrophil function, and macrophage oxidative metabolism have been reported to increase in the presence of fever [150] [151] [152] [153] [154] . However, to avoid excessively elevated body temperature affecting normal physiological functions, the body will activate sympathetic nerves and regulate circulatory function, which will increase the heart rate and cardiac output [155] . An increase in heart rate over a long period of time will lead to increased myocardial oxygen consumption and decreased cardiac output, which may cause ischemia or heart failure [156] . Many diseases with fever symptoms may be complicated by myocarditis, such as spotted fever rickettsioses infection [157] , severe fever with thrombocytopenia syndrome [158] , drug reaction with eosinophilia and systemic symptoms [159] , dengue [160] [161] [162] , complicated scrub typhus [163] , herpes simplex virus infection [164] , enteric fever [165] .

A decrease in cardiac function may occur in febrile illnesses, but whether myocardial damage is due to fever or the underlying infection is not known [166] . Weissinger et al. found that in pigs with a bacterial infection with elevated body temperature, serum CK, lactate dehydrogenase (LD), J o u r n a l P r e -p r o o f and gamma-globulin (GG) levels were increased. The administration of antibiotics to these pigs and lowering their body temperature reduced CK and LD levels, but GG levels remained elevated, suggesting that the infection did not decrease. This study indicated that the levels of CK and LD were elevated due to fever caused by infection [167] . K L et al. discovered that a longer duration of fever was related to the occurrence of pericarditis after myocardial infarction [168] . Therefore, heart injury in coronavirus infection may be related to fever .

Severe pneumonia can cause significant gas exchange disturbances and lead to hypoxemia. Hypoxia reduces the energy production required for cell metabolism and increases the body's anaerobic digestion. Acidosis and oxygen free radicals accumulated in the cell destroy the phospholipid layer of the cell membrane. As hypoxia continues, the intracellular calcium ion concentration increases significantly, leading to a series of cell damage processes, including apoptosis [169] . At the same time, hypoxia can also induce inflammatory reactions, such as the infiltration of inflammatory cells and the release of cytokines, leading to further tissue ischemia, and may even cause myocardial infarction[13, 170, 171] .

Previous lessons from coronavirus and influenza have shown that viral infections can cause acute coronary syndrome [172, 173] , arrhythmia [174] , and exacerbation of heart failure [175] , mainly due to a combination of significant systemic inflammation response and localized vascular inflammation at the arterial plaque, along with other effects [176] [177] [178] . Evidence has shown that SARS-CoV induces the expression of proinflammatory cytokines such as monocyte chemotactic protein 1 (MCP-1), transforming growth factor-beta 1 (TGF-beta1), TNF, IL-1 and IL-J o u r n a l P r e -p r o o f 6 and interferon-β (IFN-β) in SARS patients and experimental animal models infected with SARS-CoV [179, 180] . TNF and IL-1 family and IL-6 family cytokines are considered proinflammatory mediators of heart failure, and they have obvious negative inotropic effects, which may explain heart failure complications in SARS infection [181] . The acute heart injury might be due to the cytokine storm resulting from an overaggressive host immune response to SARS infection [30] . There is evidence indicating that myocardial inflammation induced by SARS-CoV is mainly mediated by macrophages and the resultant production of chemokines [95, 96] . The nuclear factor-κB (NF-κB) signaling pathway associated with the induction of proinflammatory cytokines is activated in SARS-CoV-infected mice. Treatment with drugs that inhibited NF-κB activation led to a reduction in inflammation in both SARS-CoV-infected cultured cells and mice and significantly increased mouse survival after SARS-CoV infection, indicating that the activation of the NF-κB signaling pathway represents a major contribution to the inflammation induced after SARS-CoV infection and that NF-κB inhibitors are promising antivirals in infections caused by SARS-CoV and potentially other pathogenic human coronaviruses [182] .

SARS-CoV-2 appears to affect themyocardium and cause myocarditis [128] . Myocardial injury is likely associated with infection-related myocarditis and/or ischemia [60] . Increases in inflammatory factors such as CRP, IL-1 and IL-6 were also discovered in SARS-CoV-2 infection [131, 132, 147] . Wu et al. believed that SARS-CoV-2 may cause heart damage by the cytokine storm [131] . Evidence has shown that SARS-CoV-2 may mainly affect T lymphocytes, especially CD4+ T cells, resulting in a significant decrease in lymphocyte numbers [183] . The extent of lymphopenia and an increase in inflammatory cytokines are related to the severity of the disease [147] . Critically ill COVID-19 patients had higher levels of IL6, IL10, TNFα, lactate dehydrogenase (LDH), and C-reactive protein than patients with mild COVID-19 [9, 139, 184] , suggesting that inflammatory indicators are an important factor in the early diagnosis of severe COVID-19.

Most patients with coronavirus infection are in an inflammatory state, which places the patients in a hypercoagulable state. For example, COVID-19 leads to an increase in D-dimer levels in 40% of patients, a decrease in activated partial thromboplastin time (APTT) in 16% of patients, and a decrease in PT in 30% of patients, further increasing the risk of embolism [11] . Hypercoagulability induced by inflammation might contribute to plaque rupture, with subsequent thrombosis and myocardial injury [185] . Therefore, clinicians should pay attention to COVID-19 patients with coronary heart disease to prevent myocardial injury and myocardial infarction .

Septic shock can be seen as a serious complication in SARS, MERS and COVID-19[13, 76, 103] . Approximately 6.2% of SARS-CoV-2 infections are complicated by shock [126] . It was reported that left ventricular dysfunction occurs in approximately 20% of patients within 6 hours after the onset of septic shock, and the incidence can increase to 60% by 1 to 3 days after the onset of septic shock [186] . Myocardial dysfunction and cardiovascular inflammation might lead to elevated creatine kinase and troponin [187] , which might explain the high Hs-TnI in deceased patients .

In addition to the abovementioned accompanying symptoms, anxiety and stress can also lead to adverse reactions such as accelerated heart rhythms and elevated blood pressure, especially in critically ill patients [188, 189] . Health anxiety could be found in coronavirus-infected patients [190] .

Generally, everyone experiences health anxiety to some degree, and the associated vigilance to a potential health-related threat can be protective.

However, excessive health anxiety can be detrimental [190] . The literature indicates that stress can activate the hypothalamic-pituitary-adrenal axis J o u r n a l P r e -p r o o f and sympathetic nervous system, leading to an increase in peripheral glucocorticoid and catecholamine levels [191] . High plasma catecholamine levels are associated with an increased risk of heart failure. Altered autonomic activity during depression can lead to arrhythmias. The activated SNS alters cardiac wall contractility and increases apoptotic pathways in cardiomyocytes, contributing to CVD development .

Although there is no relevant study on COVID-19 patients suffering from anxiety, medical workers have been reported to be anxious after direct contact with the patients [192, 193] . A study by Sun et al. showed that some Chinese showed acute posttraumatic stress symptoms during the COVID-19 outbreak [194] . Therefore, psychological counseling should be conducted on patients in a timely manner, and anxiolytic drugs could be used when necessary .

As mentioned above, SARS-CoV was reported to lead to myocardial infection with a marked decrease in ACE2 expression, which may be responsible for myocardial dysfunction and adverse cardiac outcomes in patients with SARS [99] . Direct SARS-CoV infection of cardiomyocytes may also lead to myocarditis and impaired myocardial function. Coronavirus-induced myocarditis and its subsequent progression to dilated cardiomyopathy have been described in rabbit models [195] . SARS-CoV was found in heart samples from patients who died of SARS [76] .

Pathological findings showed a marked increase in macrophage infiltration in patients with SARS-CoV in the heart, with evidence of myocardial damage. MERS-CoV was not detected in the heart tissue, and the heart showed no significant histological changes in MERS patients [111, 112] .

However, an animal model study clearly stated that MERS-CoV RNA could be seen in cardiac tissue, implying direct cardiac pathology [113] .

Although myocarditis was reported in sporadic autopsy cases [128] , there is still no clear pathological evidence supporting that SARS-CoV-2 can directly cause heart damage .

The most frequently used drugs during hospitalization are glucocorticoids and antiviral drugs, as well as antibiotics. The secondary QT interval prolongation caused by the use of drugs during hospitalization cannot be ignored. Antiviral drugs (lopinavir, ritonavir), antibiotics (azithromycin, moxifloxacin, levofloxacin), antifungal drugs, glucocorticoids and some antiarrhythmic drugs, there is a potential risk of prolonging the QTc interval [196, 197] . Drug-associated QT prolongation is associated with increased arrhythmic and non-arrhythmic mortality and it therefore continues to be an important metric of drug safety [198] .

A small study in France enrolling 26 treated patients and 16 non-randomized controls showed that hydroxychloroquine alone or in combination with azithromycin shortened the time to resolution of viral shedding of COVID-19 [199] . Based on this study, clinicians in many countries have begun using these medications in clinical practice, and multiple randomized trials are being initiated. But there were occasional case reports of hydroxychloroquine prolonging the QT interval and provoking torsade de pointes when used to treat systemic lupus erythematosus [200] [201] [202] [203] . The widely used antibiotic azithromycin was gradually recognized as a rare cause of prolonged QT, severe arrhythmia, and increased risk of sudden death [204] [205] [206] [207] . Although there were no reports of arrhythmia death caused by the use of hydroxychloroquine, the use of hydroxychloroquine and azithromycin should also be noted [208] .

J o u r n a l P r e -p r o o f

Active support with expected management based on early prognostic indicators may improve recovery. Appropriate treatment of heart failure, arrhythmia, acute coronary syndrome and thrombosis are still important. With continued global cooperation on multiple methods, specific evidence-based treatment strategies for COVID-19 will emerge. In order to protect the wider population, antibody testing and effective vaccines will be needed to make a history of COVID-19. And some treatment related issues need attention.

Firstly, the use of ACEI / ARB drugs was controversial in the earlier phase of COVID-19 epidemic. But recently published studies suggested that there is no need for patients with hypertension to stop using ACEI / ARB or switch to other antihypertensive medicine [60, 61, 209] . Some conjectures [210] based on the disease mechanism in the early stage of the outbreak that ACEI / ARB may increase the infection of new coronavirus and the aggravation of COVID-19 by increasing the expression of ACE2 have been denied by more and more clinical evidence. We see that the continuous treatment of COVID-19 patients with hypertension with ACEI / ARB will not only cause the deterioration of the condition, but also continue to exert cardiovascular protection and even improve the prognosis [60, 61, 209] .

Secondly, we should pay attention to the application of hydroxychloroquine [200] [201] [202] [203] and azithromycin [204] [205] [206] [207] for their side effects of prolonging the QT interval. Other drugs used to treat the COVID-19 patients, such as antiviral drugs (lopinavir, ritonavir), antibiotics (moxifloxacin, levofloxacin), antifungal drugs, glucocorticoids and some antiarrhythmic drugs, can cause the QT interval prolongation and should attract more attention. Reference by Sapp et al. would help to minimize risk of drug-induced ventricular arrhythmia during treatment of COVID-19 [211] .

Thirdly, A recent study from JAMA reported that the mortality rate of patients with mechanical ventilation treatment was 88.1% [212] . Multiple studies around the world have shown that the mortality rate of COVID-19 patients using ventilator was still high [213] [214] [215] . And it was believed that the ventilator should be used more cautiously in patients with COVID-19, which can reduce the mortality of patients using the ventilator by more than 50% [216] . New guidelines should be established for when to use a ventilator for patients with COVID-19. We advocate the application of staged breathing support methods to delay the use of ventilator. Simple oxygen treatment like nasal oxygen supply may be safer and more effective.

Fourth, methylprednisolone are the classical immunosuppressive drugs, which are important to stop or delay the progress of the pneumonia, and have been proved to be effective for the treatment of acute respiratory distress syndrome (ARDS). In recent study [217] , Wu at al. found that the administration of methylprednisolone appeared to reduce the risk of death in COVID-19 patients with ARDS. However, of those who received methylprednisolone treatment, 23 of 50 patients died. This is a rather high mortality of ~50%. The indication, timing, dosage and duration, the application of methylprednisolone needs further investigation.

Fifth, the early report showed that remdesivir was highly effective in the control of SARS-CoV-2 infection in vitro [218] . But recent study published in Lancet showed that remdesivir did not reduce the mortality of COVID-19 patients [219] . However, another clinical trial showed that remdesivir accelerates recovery from advanced COVID-19 [220] . Another clinical trial showed that there was no significant difference in clinical outcome between the 5-day and 10-day course of remdesivir [221] . These data suggested remdesivir does not reduce the mortality of COVID-19 patients, J o u r n a l P r e -p r o o f but have an effect on shortening the course of disease in mild patients. And early medication may be better. The application of remdesivir needs further researches.

Clinical data indicate that comorbid cardiovascular disease will aggravate the severity of coronavirus infection, leading to a poor prognosis.

Coronavirus may cause myocardial injury, and the prognosis of patients with complicated myocardial injury is poor. The mechanism of coronavirus causing myocardial injury and drug treatment options remain to be further studied.

The authors declared that they have no conflicts of interest to this work J o u r n a l P r e -p r o o f Abbreviation: CK, creatine kinase; LDH, lactate dehydrogenase; hs-TnI, hypersensitive troponin I; CKMB, creatine kinase-myocardial band isoenzyme; proBNP, pro brain natriuretic peptide; CRP, C-reactive protein; IL, Interleukin; TnT, troponin T. 6 (3.6%) 9 (6.7%) Death 6 (15%) 11 (11%) 5 (7.5%) 6 (4.3%) 1 (0.3%) 2 (1.2%) 1 (0.7%)

A Novel Coronavirus from Patients with Pneumonia in China

Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study

A Novel Coronavirus Emerging in China -Key Questions for Impact Assessment

World Health Organization

Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)

World Health Organization, WHO characterizes COVID-19 as a pandemic

The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in

Cryo-electron tomography of mouse hepatitis virus: Insights into the structure of the coronavirion

Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation

Coronaviruses in animals and humans

A new virus isolated from the human respiratory tract

A previously undescribed coronavirus associated with respiratory disease in humans

Identification of a new human coronavirus

Intracellular development and mechanism of hemadsorption of a human coronavirus

Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease

Cultivation of A Novel Type of Common-Cold Virus in Organ Cultures

Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia

A novel coronavirus associated with severe acute respiratory syndrome

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Coronavirus as a possible cause of severe acute respiratory syndrome

Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease

The New Coronavirus, the Current King of China

Clinical Impact of Human Coronaviruses 229E and OC43 Infection in Diverse Adult Populations

Respiratory coronavirus infections in children younger than two years of age

Epidemiology and Clinical Features of Human Coronaviruses in the Pediatric Population

MERS-CoV as an emerging respiratory illness: A review of prevention methods, Travel medicine and infectious disease

SARS and MERS: recent insights into emerging coronaviruses

Jian-xing He, Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis

The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex

Function, and Evolution of Coronavirus Spike Proteins

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

Human aminopeptidase N is a receptor for human coronavirus 229E

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov

Angiotensin-converting enzyme 2 is an essential regulator of heart function

Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Regulation of ACE2 in cardiac myocytes and fibroblasts

Lessons from SARS: control of acute lung failure by the SARS receptor ACE2

The Science Underlying COVID-19: Implications for the Cardiovascular System

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease

Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19

The association of viral and bacterial respiratory infections with exacerbations of wheezing in young asthmatic children

community-based study on virologic assessment among elderly people with and without symptoms of acute respiratory infection

Coronavirus 229E-related pneumonia in immunocompromised patients

Viral infections in patients with chronic obstructive pulmonary disease

Human Coronavirus and Acute Respiratory Illness in Older Adults with Chronic Obstructive Pulmonary Disease

Human coronaviruses: what do they cause?

Coronaviruses post-SARS: update on replication and pathogenesis

Epidemiological and clinical features of human coronavirus infections among different subsets of patients

Characterization of human coronavirus OC43 and human coronavirus NL63 infections among hospitalized children <5 years of age

Evaluation of the Temporal Association between Kawasaki Disease and Viral Infections in South Korea

Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease

Consensus document on the epidemiology of severe acute respiratory syndrome (SARS)

The severe acute respiratory syndrome epidemic in mainland China dissected

Case fatality rate of severe acute respiratory syndromes in Beijing

Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus

A comparative epidemiologic analysis of SARS in Hong Kong

The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients

Case fatality of SARS in mainland China and associated risk factors, international health

Methods for estimating the case fatality ratio for a novel, emerging infectious disease

Hku Uch Sars Study Group, Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Sars Response Team Taiwan, SARS in Taiwan: an overview and lessons learned

Clinical prognostic rules for severe acute respiratory syndrome in low-and high-resource settings

Clinical features and short-term outcomes with SARS in the greater Toronto area

A major outbreak of severe acute respiratory syndrome in Hong Kong

Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)

A cluster of cases of severe acute respiratory syndrome in Hong Kong

Clinical characteristics of fatal patients with severe acute respiratory syndrome in a medical center in Taipei

Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome

Effects of underlying cerebrocardiovascular diseases on the incidence of critical conditions and multiple organs dysfunction syndrome in severe acute respiratory syndrome cases

Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study

Cardiovascular complications of severe acute respiratory syndrome

The severe acute respiratory syndrome

SARS and other coronaviruses as causes of pneumonia

Pulmonary pathology of severe acute respiratory syndrome in

Modern pathology : an official journal of the United States and Canadian Academy of Pathology

Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome

Modulation of TNF-alphaconverting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry

Human immunopathogenesis of severe acute respiratory syndrome (SARS)

SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS

Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus

Ksa Mers-CoV Investigation Team, Hospital outbreak of Middle East respiratory syndrome coronavirus

Middle East respiratory syndrome coronavirus infections in health care workers

Basel Al Raiy, Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection

Community case clusters of Middle East respiratory syndrome coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: a descriptive genomic study

Makhdoom, Alimuddin I. Zumla, Ziad A. Memish, Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study

Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients

Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis

Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia

Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus

Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection -clinicopathological and ultrastructural study

Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates

Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease

A novel coronavirus genome identified in a cluster of pneumonia cases-Wuhan

A novel coronavirus outbreak of global health concern

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

World Health Organization

Feng Z, Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan

Importation and Human-to-Human Novel Coronavirus in Vietnam

Clinical characteristics of novel coronavirus cases in tertiary hospitals in

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Acute Myocardial Injury of Patients with Coronavirus Disease

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis, Travel medicine and infectious disease

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Cardiac Involvement in a Patient With Coronavirus Disease

Yuan Fang, Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin

Heart injury signs are associated with higher and earlier mortality in coronavirus disease

Clinical characteristics of 82 death cases with COVID-19

Laboratory abnormalities in patients with COVID-2019 infection

Clinical features and outcomes of coronavirus-infected patients with cardiac injury

Prognostic value of NT-proBNP in patients with severe COVID-19

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

The global population of SARS-CoV-2 is composed of six major subtypes

On the origin and continuing evolution of SARS-CoV-2

Clinical Features of 69 Cases with Coronavirus Disease

Clinical characteristics of imported and second-generation COVID-19 cases outside Wuhan, China: A multicenter retrospective study

Connecting type 1 and type 2 diabetes through innate immunity, Cold Spring Harbor perspectives in medicine

Inflammation and cardiovascular disease: from pathogenesis to therapeutic target

Inflammation, Immunity, and Hypertension

Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension

Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected medRxiv (2020)

Network-based analysis of comorbidities risk during an infection: SARS and HIV case studies

Prevalence of human coronaviruses in adults with acute respiratory tract infections in Beijing

Cellular and humoral aspects of the influence of environmental temperature on the immune response of poikilothermic vertebrates

Fever and immunoregulation. III. Hyperthermia augments the primary in vitro humoral immune response

Hyperthermia and human leukocyte function. II. Enhanced production of and response to leukocyte migration inhibition factor (LIF)

Effect of hyperthermia on rabbit macrophages

Effect of temperature on the chemotaxis, phagocytic engulfment, digestion and O2 consumption of human polymorphonuclear leukocytes

Some responses of the cardiovascular system to heat and fever

Spotted fever rickettsioses causing myocarditis and ARDS: a case from Sri Lanka

Fulminant myocarditis associated with severe fever with thrombocytopenia syndrome: a case report

Myocarditis Associated with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Case Report and Review of the Literature

Heart and liver are infected in fatal cases of dengue: three PCR based case studies

Dengue Myocarditis: An Important Clinical Entity to Consider in Dengue Patient

Acute myocarditis in dengue hemorrhagic fever: a case report and review of cardiac complications in dengue-affected patients

Predictors of acute myocarditis in complicated scrub typhus: an endemic province in the Republic of Korea

A case report of myocarditis combined with hepatitis caused by herpes simplex virus

Myocarditis in enteric fever

Systolic time intervals in febrile states

Serum enzyme abnormalities in swine associated with systemic infection and fever

Pericarditis in acute myocardial infarction

Effect of oxygen deprivation on the metabolism of fetal and adult tissues

Cellular adaptive responses to low oxygen tension: apoptosis and resistance

Nursing Council Cardiovasc Stroke, Prevention Council Epidemiology, Res Council Quality Care Outcomes, Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the

Casscells, 3rd, Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects

Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection

Effect of High Influenza Activity on Risk of Ventricular Arrhythmias Requiring Therapy in Patients With Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Association of Influenza-like Illness Activity With Hospitalizations for Heart Failure: The Atherosclerosis Risk in Communities Study

Influenza vaccination: a one-shot deal to reduce cardiovascular events

Influenza and cardiovascular disease: is there a causal relationship?

Role of acute infection in triggering acute coronary syndromes

The replication of a mouse adapted SARS-CoV in a mouse cell line stably expressing the murine SARS-CoV receptor mACE2 efficiently induces the expression of proinflammatory cytokines

Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS

Inflammatory mediators and the failing heart: past, present, and the foreseeable future

Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival

Qin Ning, Clinical and immunologic features in severe and moderate forms of Coronavirus Disease

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Altered preoperative coagulation and fibrinolysis are associated with myocardial injury after non-cardiac surgery

Actual incidence of global left ventricular hypokinesia in adult septic shock

Impacts of sepsis-induced myocardial dysfunction on hemodynamics, organ function and prognosis in patients with septic shock

Immediate and sustained psychological impact of an emerging infectious disease outbreak on health care workers

The impact of epidemic outbreak: the case of severe acute respiratory syndrome (SARS) and suicide among older adults in Hong Kong

Health Anxiety: Current Perspectives and Future Directions

SnapShot: Stress and Disease

The prevalence and influencing factors for anxiety in medical workers fighting COVID-19 in China: A cross-sectional survey

Emotional responses and coping strategies of nurses and nursing college students during COVID-19 outbreak

Prevalence and Risk Factors of Acute Posttraumatic Stress Symptoms during the COVID-19 Outbreak

Electrocardiographic changes following rabbit coronavirus-induced myocarditis and dilated cardiomyopathy

Blockade of HERG channels by HIV protease inhibitors

Drug-induced QT Interval Prolongation in the Intensive Care Unit

Association of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia

Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus

Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine

Toxicokinetics of hydroxychloroquine following a massive overdose

Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study

Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors

Azithromycin and the risk of cardiovascular death

Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study

The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension

Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19

Guidance On Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease

Respiratory Support in Novel Coronavirus Disease (COVID-19) Patients, with a Focus on Resource-Limited Settings

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Remdesivir and chloroquine effectively inhibit the coronavirus (2019-nCoV) in vitro

National Institutes of Health, NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19

Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19-Study Demonstrates Similar Efficacy with 5-and 10-Day Dosing Durations of Remdesivir

J o u r n a l P r e -p r o o f

Abbreviation: CDC, Chinese Center for Disease Control and Prevention; PICU, pediatric intensive care unit; ICU: intensive care unit. Li